

July 2021 - Volume 27 - Issue 4

- Previous Abstract
- Next Abstract

- **Cite**
  - Copy
  - Export to RIS
  - Export to EndNote
- **Share**
  - Email
  - Facebook
  - Twitter
  - LinkedIn
- **Favorites**
- **Permissions**
- **More**
  - Cite
  - Permissions

NEOPLASMS OF THE LUNG: Edited by Alan Fein and David E. Ost

# The evolving paradigm of precision medicine in lung cancer

Passiglia, Francesco; Scagliotti, Giorgio V.

## Author Information

Department of Oncology, University of Turin, San Luigi Hospital, Turin, Italy

Correspondence to Giorgio V. Scagliotti, MD, PhD, Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Turin, Italy. E-mail: giorgio.scagliotti@unito.it

Current Opinion in Pulmonary Medicine: July 2021 - Volume 27 - Issue 4 - p 249-254

doi: 10.1097/MCP.0000000000000778

- Buy

Metrics

## Abstract

### Purpose of review

In this review, we report a complete and updated summary of the most recent treatment advances in the fields of oncogene-addicted disease and provide expert perspectives on the evolving paradigm of precision medicine in lung cancer patients.

### Recent findings

The advent of innovative genome sequencing technologies is rapidly increasing the number of targetable molecular alterations in advanced nonsmall cell lung cancer (NSCLC), leading to the introduction of novel selective inhibitors into the clinical arena, showing unprecedented tumor responses against rare and elusive NSCLC targets. The results of the ADAURA trial suggested that targeting EGFR pathway in the adjuvant setting is a feasible and effective strategy. The routine use of next-generation sequencing (NGS) is currently recommended as new standard approach to profile advanced NSCLC samples while recent findings suggest the potential application of a plasma-based first approach for tumor genotyping. Innovative umbrella trials provide the right infrastructure to investigate the role of precision medicine in advanced NSCLC, but failed to show clinical benefit.

## Summary

Implementing NGS-based molecular screening, increasing patients' access to biomarker driven-clinical trials, ensuring equal access to molecular testing and innovative treatments, overcoming disparities and preserve health systems' financial sustainability represents the main challenges of precision medicine worldwide.

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

[^Back to Top](#)



Never Miss an Issue

Get new journal Tables of Contents sent right to your email inbox

Browse Journal Content

- Most Popular
- For Authors
- About the Journal
- Past Issues

- [Current Issue](#)
- [Register on the website](#)
- [Subscribe](#)
- [Get eTOC Alerts](#)

#### For Journal Authors

- [Submit an article](#)
- [How to publish with us](#)

#### Customer Service

- [Activate your journal subscription](#)
- [Activate Journal Subscription](#)
- [Browse the help center](#)
- [Help](#)
- [Contact us at:](#)
  - **EMAIL:**  
[customerservice@lww.com](mailto:customerservice@lww.com)
  - **TEL: (USA):**  
**TEL: (Int'l):**  
800-638-3030 (within USA)  
301-223-2300 (international)



- [Privacy Policy \(Updated June 1, 2020\)](#)
- [Legal Disclaimer](#)
- [Terms of Use](#)
- [Open Access Policy](#)
- [Feedback](#)
- [Sitemap](#)
- [RSS Feeds](#)
- [LWW Journals](#)
- [Copyright © 2021](#)
- [Wolters Kluwer Health, Inc. and/or its subsidiaries. All rights reserved.](#)

×

## Login

*No user account? Register for free. Register for free.*

Lippincott Journals Subscribers, use your username or email along with your password to log in.

<input type="text" value="Email or Username"/>	⊗ ⊙
<input type="password" value="Password"/>	⊗ ⊙

[Forgot Password?](#)